Celldex Therapeutics will stop developing its top drug barzolvolimab in eczema after the therapy did not prove impactful enough in a Phase 2 study and missed the company’s internal hurdle rate for continued development. The drug has now fallen short in Phase 2 testing in two other immune conditions, but Celldex is still planning an approval filing in chronic hives after success in a pair of late stage trials. Several analysts defended the company, calling expectations for the eczema study low and the failure immaterial to the investment case; Stifel’s Alex Thompson wrote that the key debate is barzolvolimab’s place in the growing market for chronic spontaneous urticaria treatments.
nChroma Bio halted testing of its lead programme in hepatitis B, will evaluate strategic alternatives, and disclosed plans to cut staff and restructure; the company, formed in a 2024 merger of Chroma Medicine and Nvelop Therapeutics, had positioned CRMA-1001 as a possible functional cure for chronic hepatitis B, and will reportedly lay off around half its workforce. VitriVax secured $87 million in Series C financing from F-Prime Capital, RA Capital, NEA and the venture arms of Eli Lilly and Sanofi to start the first human trial of a Lyme disease vaccine designed to protect with a single dose and without an adjuvant.